Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Research Domains
  1. Home
  3. Research Domains

Related Concept Videos

  • Biomedical And Clinical Sciences
  • Oncology And Carcinogenesis
  • Predictive And Prognostic Markers
  • Claudin 18.2 As A New Biomarker In Gastric Cancer-what Should We Know?
  • Biomedical And Clinical Sciences
  • Oncology And Carcinogenesis
  • Predictive And Prognostic Markers
  • Claudin 18.2 As A New Biomarker In Gastric Cancer-what Should We Know?

    • Related Experiment Video

    Elastic Staining on Paraffin-embedded Slides of pT3N0M0 Gastric Cancer Tissue
    06:36

    Elastic Staining on Paraffin-embedded Slides of pT3N0M0 Gastric Cancer Tissue

    Published on: May 1, 2019

    7.1K

    Claudin 18.2 as a New Biomarker in Gastric Cancer-What Should We Know?

    Maria Cecília Mathias-Machado1, Victor Hugo Fonseca de Jesus2, Alexandre Jácome3

    • 1Division of Gastrointestinal Medical Oncology, Oncoclínicas, São Paulo 04538-132, Brazil.

    Cancers
    |February 10, 2024

    View abstract on PubMed

    Summary
    This summary is machine-generated.

    Claudin 18.2 (CLDN18.2) is a promising biomarker for gastric cancer (GC). Targeting CLDN18.2 with Zolbetuximab shows efficacy in metastatic GC, guiding future treatment decisions.

    Keywords:
    biomarkerscancergastric cancertreatment

    More Related Videos

    Detection of a CDH1 Rare Transcript Variant in Fresh-frozen Gastric Cancer Tissues by Chip-based Digital PCR
    09:16

    Detection of a CDH1 Rare Transcript Variant in Fresh-frozen Gastric Cancer Tissues by Chip-based Digital PCR

    Published on: February 5, 2018

    6.2K
    Three-Dimensional Culture of Murine Colonic Crypts to Study Intestinal Stem Cell Function Ex Vivo
    07:46

    Three-Dimensional Culture of Murine Colonic Crypts to Study Intestinal Stem Cell Function Ex Vivo

    Published on: October 11, 2022

    3.3K

    Related Experiment Videos

    Elastic Staining on Paraffin-embedded Slides of pT3N0M0 Gastric Cancer Tissue
    06:36

    Elastic Staining on Paraffin-embedded Slides of pT3N0M0 Gastric Cancer Tissue

    Published on: May 1, 2019

    7.1K
    Detection of a CDH1 Rare Transcript Variant in Fresh-frozen Gastric Cancer Tissues by Chip-based Digital PCR
    09:16

    Detection of a CDH1 Rare Transcript Variant in Fresh-frozen Gastric Cancer Tissues by Chip-based Digital PCR

    Published on: February 5, 2018

    6.2K
    Three-Dimensional Culture of Murine Colonic Crypts to Study Intestinal Stem Cell Function Ex Vivo
    07:46

    Three-Dimensional Culture of Murine Colonic Crypts to Study Intestinal Stem Cell Function Ex Vivo

    Published on: October 11, 2022

    3.3K

    Area of Science:

    • Oncology
    • Gastroenterology
    • Molecular Biology

    Background:

    • Gastric cancer (GC) is a leading cause of cancer mortality globally, with poor survival rates for advanced stages.
    • Current first-line treatments for metastatic GC lack predictive molecular markers, highlighting an unmet clinical need.
    • Claudin 18.2 (CLDN18.2) has emerged as a significant biomarker in GC.

    Purpose of the Study:

    • To review the evolving role of CLDN18.2 as a biomarker in gastric cancer.
    • To explore the current clinical development status of CLDN18.2-targeting agents.
    • To provide insights into CLDN18.2's therapeutic potential for metastatic GC management.

    Main Methods:

    • Review of recent phase III clinical trials focusing on CLDN18.2.
    • Analysis of the efficacy of CLDN18.2-targeting therapies, such as Zolbetuximab.
    • Evaluation of decision-making criteria for selecting anti-CLDN18.2 therapies.

    Main Results:

    • Zolbetuximab, a CLDN18.2-targeting antibody, demonstrates efficacy in combination with chemotherapy for CLDN18.2-positive metastatic GC.
    • CLDN18.2 is a validated predictive biomarker for response to targeted therapy.
    • Emerging CLDN18.2-targeting agents are advancing in clinical development.

    Conclusions:

    • CLDN18.2 represents a promising therapeutic target for a subset of patients with metastatic gastric cancer.
    • Understanding CLDN18.2 status is crucial for optimizing treatment selection in advanced GC.
    • Targeted therapies against CLDN18.2 offer a new avenue for improving outcomes in gastric cancer.